Key Findings
The FDA approved the combination of durvalumab (Imfinzi) and enfortumab vedotin (EV; Padcev) for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or have refused cisplatin-based chemotherapy. Based on the phase 3 VOLGA trial, the regimen demonstrated a 24-month event-free survival (EFS) of 63.5% compared to 45.1% for surgery alone (HR 0.51). The 24-month overall survival (OS) was 78.4% versus 69.4% (HR 0.58), representing a 42% reduction in the risk of death.
Technical Details
The approved perioperative regimen consists of three 21-day cycles of durvalumab (1500 mg) plus EV (1.25 mg/kg) administered before bladder removal, followed by radical cystectomy and nine cycles of adjuvant durvalumab every four weeks. Pathologic complete response was achieved in 45.1% of patients in the durvalumab-EV arm, compared to 9.6% in the surgery-only arm. Grade ≥3 adverse events occurred in 71.1% of the durvalumab-EV group versus 50.2% in the control group, with notable EV-related events including skin reactions (48.7%) and neuropathy (17.5%).
A triplet arm adding tremelimumab improved EFS (24-month EFS 60.1%; HR 0.61) but did not improve OS and increased toxicity and discontinuations.
Background & Context
Approximately 1 in 4 bladder cancer patients have muscle-invasive disease, and up to half are cisplatin-ineligible due to comorbidities or impaired kidney function. While the NIAGARA trial established perioperative durvalumab plus cisplatin for eligible patients, and other regimens combine EV with pembrolizumab both before and after surgery, the VOLGA trial specifically tested a regimen that limits the antibody-drug conjugate (EV) to the pre-surgical phase.
Significance & Outlook
This approval introduces the first perioperative regimen where EV is administered only before surgery. The data suggests that concentrating EV before the stress of surgery, while maintaining immunotherapy on both sides of the cystectomy, offers a manageable safety profile and substantial neoadjuvant cytoreduction. Cystectomy rates were higher in the durvalumab-EV group (85.0% vs 78.6%), with only 0.9% of cancellations driven by adverse events.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime



